Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting
Maxime Battistella, Christophe Lebœuf, C. Ram‐Wolff, et al.
Blood (2017) Vol. 130, Iss. 26, pp. 2900-2902
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
Johanna Latzka, Chalid Assaf, M. Bagot, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113343-113343
Open Access | Times Cited: 67
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
M. Bagot, Pierluigi Porcu, Anne Marie‐Cardine, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 8, pp. 1160-1170
Open Access | Times Cited: 141
Advances in targeted therapy for malignant lymphoma
Li Wang, Wei Qin, Yujia Huo, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 102
Single-cell transcriptomics links malignant T cells to the tumor immune landscape in cutaneous T cell lymphoma
Xiangjun Liu, Shanzhao Jin, Simeng Hu, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 57
Pathogenesis and Therapy of Primary Cutaneous T-Cell Lymphoma: Collegium Internationale Allergologicum (CIA) Update 2020
Małgorzata Bobrowicz, Christina Fassnacht, Desislava Ignatova, et al.
International Archives of Allergy and Immunology (2020) Vol. 181, Iss. 10, pp. 733-745
Open Access | Times Cited: 42
Novel Treatments of Adult T Cell Leukemia Lymphoma
Hiba El Hajj, Kunihiro Tsukasaki, Morgane Cheminant, et al.
Frontiers in Microbiology (2020) Vol. 11
Open Access | Times Cited: 40
Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome
Safa Najidh, Cornelis P. Tensen, Alita J. van der Sluijs‐Gelling, et al.
Blood (2021) Vol. 138, Iss. 24, pp. 2539-2554
Open Access | Times Cited: 38
The Diagnostic Utility of TRBC1 Immunohistochemistry in Mature T-Cell Lymphomas
Ting Zhou, Rohan Sardana, Özgür Can Eren, et al.
Modern Pathology (2025), pp. 100725-100725
Closed Access
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)
Katherine Case, Pamela B. Allen
Current Hematologic Malignancy Reports (2025) Vol. 20, Iss. 1
Closed Access
Brentuximab vedotin in T-cell lymphoma
Carrie Van Der Weyden, Michael Dickinson, James C. Whisstock, et al.
Expert Review of Hematology (2018) Vol. 12, Iss. 1, pp. 5-19
Closed Access | Times Cited: 34
Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR 3 DL 2 marker
Marie Roelens, Adèle de Masson, C. Ram‐Wolff, et al.
British Journal of Dermatology (2019) Vol. 182, Iss. 6, pp. 1415-1422
Closed Access | Times Cited: 30
Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update
Egle Ramelyte, Reinhard Dummer, Emmanuella Guenova
Expert Opinion on Investigational Drugs (2019) Vol. 28, Iss. 9, pp. 799-809
Closed Access | Times Cited: 17
KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma
Amandine Decroos, Morgane Cheminant, Julie Bruneau, et al.
Haematologica (2023) Vol. 108, Iss. 10, pp. 2830-2836
Open Access | Times Cited: 5
Monoclonal Antibodies in Dermatooncology—State of the Art and Future Perspectives
Małgorzata Bobrowicz, Radosław Zagożdżon, J Domagała, et al.
Cancers (2019) Vol. 11, Iss. 10, pp. 1420-1420
Open Access | Times Cited: 15
KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target
Morgane Cheminant, Ludovic Lhermitte, Julie Bruneau, et al.
Blood (2022) Vol. 140, Iss. 13, pp. 1522-1532
Open Access | Times Cited: 8
Diagnosis and treatment of lymphomas in the era of epigenetics
Alain Chebly, Éliane Chouery, Joana Ropio, et al.
Blood Reviews (2020) Vol. 48, pp. 100782-100782
Closed Access | Times Cited: 12
Single-cell RNA sequencing comparison of CD4+, CD8+ and TCR-γδ+ cutaneous T-cell lymphomas reveals subset-specific molecular phenotypes
Sumanth Chennareddy, Katharina Rindler, J. Ruggiero, et al.
British Journal of Dermatology (2024)
Open Access | Times Cited: 1
IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma
Carrie Van Der Weyden, M. Bagot, Paul J. Neeson, et al.
Expert Opinion on Investigational Drugs (2018) Vol. 27, Iss. 8, pp. 691-697
Closed Access | Times Cited: 12
CCR8 is a new therapeutic target in cutaneous T-cell lymphomas
Jérôme Giustiniani, Gábor Dobos, Hélène Moins‐Teisserenc, et al.
Blood Advances (2022) Vol. 6, Iss. 11, pp. 3507-3512
Open Access | Times Cited: 7
Novel therapeutic approaches for cutaneous T cell lymphomas
Antreas Pavlidis, Christina Piperi, Evangelia Papadavid
Expert Review of Clinical Immunology (2021) Vol. 17, Iss. 6, pp. 629-641
Closed Access | Times Cited: 9
Differential Regulation of NK Cell Receptors in Acute Lymphoblastic Leukemia
Le Jie Lee, Norfarazieda Hassan, Siti Zuleha Idris, et al.
Journal of Immunology Research (2022) Vol. 2022, pp. 1-13
Open Access | Times Cited: 6
How molecular advances may improve the diagnosis and management of PTCL patients
Fanny Drieux, François Lemonnier, Philippe Gaulard
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Image‐guided lymph node core‐needle biopsy predicts survival in mycosis fungoides and Sézary syndrome*
Julien Calvani, Adèle de Masson, Constance de Margerie‐Mellon, et al.
British Journal of Dermatology (2021) Vol. 185, Iss. 2, pp. 419-427
Closed Access | Times Cited: 8
Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies
Till Braun, Alexandra Schrader
Cancers (2023) Vol. 15, Iss. 9, pp. 2532-2532
Open Access | Times Cited: 2
mAb14, a Monoclonal Antibody against Cell Surface PCNA: A Potential Tool for Sezary Syndrome Diagnosis and Targeted Immunotherapy
Jamal Knaneh, Emmilia Hodak, Shlomit Fedida-Metula, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4421-4421
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top